Vocal fold paralysis following first dose of Oxford-AstraZeneca coronavirus disease 2019 vaccine

G M Jama, M Amin, A Hassaan and H Kaddour

Department of Otolaryngology, Queen’s Hospital, Romford, UK

Abstract

Background. In a bid to end the ongoing coronavirus disease 2019 pandemic, many countries, including the UK, have rolled out mass immunisation programmes. While considered generally safe and effective, vaccines against coronavirus disease 2019 have been reported to be associated with rare and potentially adverse reactions and side effects.

Case report. This paper reports an unusual case of a patient who developed unilateral vocal fold paralysis shortly after receiving the first dose of the Oxford-AstraZeneca ChAdOx1 nCov-19 vaccine.

Conclusion. To our knowledge, this is the first reported case of vocal fold paralysis following administration of the Oxford-AstraZeneca vaccine. The authors support the position that currently approved coronavirus disease 2019 vaccines remain safe and effective; however, further surveillance and vigilance using real-world data are highly encouraged.

Introduction

The ongoing global pandemic has resulted in 168,040,871 confirmed cases of coronavirus disease 2019 (Covid-19) and has claimed the lives of 3,494,758 people worldwide, at the time of writing. On 8 December 2020, the United Kingdom became the first country in the world to implement a national vaccination programme, following approval of the Pfizer-BioNTech messenger RNA (mRNA) vaccine (BNT162b2) by the Medicines and Healthcare products Regulatory Agency (MHRA). Since then, the roll-out has expanded to include two further vaccines – the Oxford-AstraZeneca adenovirus vector vaccine, ChAdOx1 nCov-19 (AZD1222), and the Moderna mRNA-1273 vaccine.

Data from clinical trials and national surveillance programmes support the effectiveness of currently approved vaccines in preventing severe infection, hospitalisation and death as a result of Covid-19. Furthermore, there is growing evidence to suggest a marked and sustained decline in the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), corresponding to an increase in vaccine coverage in the general population.

However, as with any new medicines, once vaccines have been approved for the use in people, there is a need to continuously and proactively collect and monitor data outside of the clinical trials setting, to improve our understanding of their safety profile. Known reported side effects of Covid-19 vaccines include localised and systemic reactions that are typically moderate in frequency, mild in severity and relatively short-lived. There have been a small number of reports of rare concurrent thrombocytopaenia and thromboembolic events observed in vaccinated individuals, although a definitive causal link remains to be proven.

This article reports an unusual and, to our knowledge, not previously described case of a patient who developed new-onset dysphonia within days of receiving the first dose of the Oxford-AstraZeneca ChAdOx1 nCov-19 vaccine.

Case report

A 52-year-old man was referred to the otolaryngology clinic on the 2-week-wait suspected cancer referral pathway with a 4-week history of persistent dysphonia. He reported experiencing intermittent episodes of coughing and choking when attempting to swallow food and drink. He had no other associated ‘red flag’ symptoms related to his upper aerodigestive tract. There was no history of unintentional weight loss or systemic symptoms. He denied any preceding laryngeal trauma, upper respiratory tract infection or clinical features suggestive of underlying gastroesophageal reflux disease.

He reported that his otherwise unexplained symptoms had developed 3 days after receiving the first dose of the Oxford-AstraZeneca ChAdOx1 nCov-19 vaccine. Although he had initially experienced some mild injection site pain and swelling, he reported no other adverse reactions to the vaccine.

His past medical history included hypertension, type 2 diabetes mellitus, hypercholesterolaemia, atrial fibrillation, ischaemic heart disease, myocardial infarction and cardiac...
pacemaker insertion. His regular medications included ramipril, eplerenone, metformin, glitazide, linagliptin, atorvastatin, edoxaban and bisoprolol. He was a smoker with a 15 pack-year history.

On examination, fibre-optic laryngoscopy revealed a paralysed right hemilarynx, with the right vocal fold in the paramedian position. The left vocal fold, although moving adequately, was not fully compensating for the contralateral vocal fold palsy, resulting in incomplete glottic closure and a phonatory gap (Figure 1). There were no overt mucosal lesions seen in the upper airway. The remainder of the physical examination was unremarkable. Specifically, there were no palpable cervical lymph nodes.

A computed tomography scan including the skull base, neck and thorax was organised. Particular attention was paid to the course of the right vagus and recurrent laryngeal nerves, which was found to be unremarkable. There was some evidence of bilateral mild to moderate pulmonary emphysema, particularly in the upper lobes, as well as features of mild bronchiectasis in the lower lobes of the lung. There were also a small number of right-sided paratracheal and hilar lymph nodes measuring 11 mm in maximum diameter.

He was referred to the speech and language therapy department to assist in his further assessment, and to offer therapy to optimise his vocal and swallowing function. He remains under follow up within our department to monitor his ongoing progress.

Discussion

Vocal fold paralysis is the restriction of vocal fold movement due to either a mechanical fixation or a neurological deficit. This can result from a number of aetiologies, including malignancy, trauma, iatrogenic injury, endotracheal intubation or central nervous system disease.8 Iatrogenic injury as a result of surgery remains the most common cause of unilateral vocal fold paralysis.8

It has been postulated that some forms of vocal fold immobility are idiopathic and may be related to viral infections.10 The pathophysiology of this process is considered to be analogous to viral-induced polynuerositis associated with Guillain–Barré syndrome, or cranial neuropathies such as Bell’s palsy, trigeminal neuralgia or glossopharyngeal neuralgia.11

While most post-viral neuropathies have been linked to acute infections, some have been observed after vaccination using the influenza, shingles, pneumococcus and hepatitis B vaccines.12 More recent reports have raised a possible temporal association between the administration of the Pfizer-BioNTech and the Oxford-AstraZeneca vaccines and the incidence of Guillain–Barré syndrome and Bell’s palsy in vaccinated individuals.13–16

Biological mechanisms have been proposed that might explain the observed association between the use of mRNA vaccines, such as the Pfizer-BioNTech vaccine, and the imbalance in the incidence of Bell’s palsy in the vaccine groups compared to placebo groups. These include the suggestion that mRNA vaccines are associated with a marked type I interferon response, which, in some individuals, may trigger and mediate a breakdown of tolerance to myelin sheath antigens, leading to autoimmune neuropathy.17

Unlike vaccines using mRNA technology, however, the Oxford-AstraZeneca vaccine consists of a replication-deficient (inactivated) chimpanzee adenovirus vector expressing the full-length SARS-CoV-2 spike (S) protein. Following intramuscular administration of the vaccine, the spike proteins are expressed locally, allowing the immune system to mount a neutralising cellular and humoral response.18 A proposed mechanism linking the ChAdOx1 nCov-19 vaccine to the development of neuropathy has yet to be described, although it is possible that the underlying process may be mediated by an immune response comparable to the recently observed phenomenon of vaccine-induced immune thrombocytopenia.19

Conclusion

To the best of our knowledge, this is the first reported case of vocal fold paralysis following administration of the Oxford-AstraZeneca ChAdOx1 nCov-19 vaccine. Although the clinical presentation may be entirely incidental, and certainly no cause and effect can be concluded at this time, this report raises an important and timely issue around vaccine safety. As with the development of any new vaccine or medicine, the size of clinical trial cohorts invariably means that very rare side effects can only be identified and fully characterised once the product is used in large populations. The authors support the position that the Oxford-AstraZeneca ChAdOx1 nCov-19 vaccine remains safe and effective; however, further surveillance and vigilance using real-world data are highly encouraged.

Competing interests. None declared

References

1 World Health Organization. WHO Coronavirus (COVID-19) Dashboard. In: https://covid19.who.int/ [27 May 2021]
2 Gov.uk. COVID-19 vaccination: information for healthcare practitioners. In: https://www.gov.uk/government/publications/covid-19-vaccination-programme-guidance-for-healthcare-practitioners [27 May 2021]
3 Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021;373:n1088

4 Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819–29

5 Yellow Card Vaccine Monitor, Medicines and Healthcare products Regulatory Agency. In: https://vaccinemonitor-yellowcard.mhra.gov.uk/ [27 May 2021]

6 Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis 2021;21:939–49

7 Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet 2021;397:1441–3

8 Rosenthal LH, Benninger MS, Deeb RH. Vocal fold immobility: a longitudinal analysis of etiology over 20 years. Laryngoscope 2007;117:1864–70

9 Spataro EA, Grindler DJ, Paniello RC. Etiology and time to presentation of unilateral vocal fold paralysis. Otolaryngol Head Neck Surg 2014;151:286–93

10 Rees CJ, Henderson AH, Belafsky PC. Postviral vagal neuropathy. Ann Otol Rhinol Laryngol 2009;118:247–52

11 Amin MR, Koufman JA. Vagal neuropathy after upper respiratory infection: a viral etiology? Am J Otolaryngol 2001;22:251–6

12 Talmor G, Nguyen B, Din-Lovinescu C, Paskhover B, Kaye R. Vocal fold immobility following vaccination. Ann Otol Rhinol Laryngol 2021;130:609–13

13 Patel SU, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep 2021;14:e242956

14 Colella G, Orlandi M, Cirillo N. Bell’s palsy following COVID-19 vaccination. J Neurol 2021;268:3589–91

15 Shemer A, Pras E, Hecht I. Peripheral facial nerve palsy following BNT162b2 (COVID-19) vaccination. Isr Med Assoc J 2021;23:143–4

16 Repajic M, Lai XL, Xu P, Liu A. Bell’s palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy. Brain Behav Immun Health 2021;13:100217

17 Soeiro T, Salvo F, Pariente A, Grandvuillemin A, Jonville-Béra AP, Micaleff J. Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell’s palsy. Therapie 2021;76:363–7

18 Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467–78

19 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2092–101